Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
123I-cT84.66
- Development stage
- Unknown
- Lead developer
- City of Hope National Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
123I-cT84.66 is a radiolabeled chimeric monoclonal antibody developed for the diagnostic imaging of tumors expressing Carcinoembryonic Antigen (CEA). The molecule consists of the cT84.66 antibody, a chimeric version of the murine monoclonal antibody T84.66, which has been engineered to reduce immunogenicity while maintaining high affinity for CEA (CEACAM5). CEA is a cell-surface glycoprotein that is significantly overexpressed in various solid tumors, most notably colorectal, gastric, and pancreatic carcinomas. By labeling the antibody with Iodine-123, a gamma-emitting radioisotope, the agent enables the non-invasive localization of CEA-positive lesions using Single Photon Emission Computed Tomography (SPECT). This diagnostic tool is primarily utilized to assess the extent of metastatic disease, identify candidates for subsequent radioimmunotherapy, and monitor treatment response in patients with gastrointestinal malignancies.
- Other names
- 123I-labeled chimeric T84.66 monoclonal antibodyIodine-123 chimeric T84.66Iodine123 chimeric T84.66Iodine 123 chimeric T84.66123I-cT84.66 antibody123I-anti-CEA chimeric antibody
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on 123I-cT84.66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 123I-cT84.66.